The molecular bacterial load assay predicts treatment responses in patients with pre-XDR/XDR-tuberculosis more accurately than GeneXpert Ultra MTB/Rif
Journal of Infection·
- DOI
- 10.1016/j.jinf.2024.106399
- PMID
- 39733827
- PMCID
- —
- OpenAlex
- W4405825783
- Study type
- Cohort study
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
Early detection of treatment failure is critical for improving drug-resistant tuberculosis management. MBLA demonstrated superior early identification of successful culture conversion compared to existing tests and may serve as a useful biomarker for evaluating novel anti-tuberculosis agents in early-phase clinical trials.
Structured evidence summary
Research question
The study evaluated whether the molecular bacterial load assay (MBLA) could serve as a reliable tool for monitoring treatment response in patients with drug-resistant pulmonary tuberculosis, specifically comparing its performance against standard diagnostic methods including culture, GeneXpert, and microscopy.
Study design
A prospective cohort study enrolled patients with pulmonary MDR/RR- and pre-XDR/XDR-tuberculosis to compare MBLA performance in tracking treatment response against mycobacterial culture, GeneXpert, and microscopy detection of sputum acid-fast bacilli, using culture conversion as the primary read-out.
Population and setting
Patients with pulmonary MDR/RR- and pre-XDR/XDR-tuberculosis were enrolled prospectively; additional geographic or clinical setting details are not specified in the available abstract.
Main findings
MBLA demonstrated higher concordance with culture results overall (72.1%) compared to Xpert (57.4%), though slightly lower than microscopy (76.7%). During early treatment, MBLA detected changes in bacterial load with similar accuracy to microscopy and outperformed Xpert. The area under the ROC curve for predicting culture conversion was 0.88 for MBLA, 0.78 for Xpert, and 0.77 for microscopy.
Public-health relevance
Early detection of treatment failure is critical for improving drug-resistant tuberculosis management. MBLA demonstrated superior early identification of successful culture conversion compared to existing tests and may serve as a useful biomarker for evaluating novel anti-tuberculosis agents in early-phase clinical trials.
Important limitations
This summary is limited to the supplied single-article abstract and metadata. Interpretation is constrained by incomplete information regarding study sample size, follow-up duration, specific patient demographics, and potential selection or information biases inherent to the study design.
GIDS interpretation
This study addresses a diagnostic gap in drug-resistant tuberculosis treatment monitoring. While findings suggest MBLA may offer improved early detection of treatment response compared to standard methods, these findings are derived from a single prospective cohort and require independent replication. The abstract alone does not support conclusions about surveillance applicability or real-world implementation readiness.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 9 auditable classifier relationships to diseases, places, topics, and study design.